Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 367

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 367
---
 and the Company recorded financing costs based on the grant date fair value of the New Series B Warrants to other expense in the accompanying statement of operations for the year
ended December 31, 2023.

F-26

LB Pharmaceuticals Inc Notes to Financial Statements Warrants outstanding as of December 31, 2024 and 2023 are as follows:

|                            |     | As of December 31, |           |     |      |           |
|                            |     |               2024 |           |     | 2023 |           |
| Class A Warrants           |     |                    |   695,961 |     |      |   695,961 |
| Class B Warrants           |     |                    |   882,948 |     |      |   886,698 |
| Series B-1 Warrants        |     |                    |    71,761 |     |      |    73,199 |
| New Series B Warrants      |     |                    |    98,456 |     |      |   100,373 |
| Placement agent warrants   |     |                    | 1,528,632 |     |      | 1,528,632 |
| Total warrants outstanding |     |                    | 3,277,758 |     |      | 3,284,863 |

See Note 3 Fair Value Measurementsfor warrant activity for the years ended December 31, 2024 and 2023. 9. Net Loss per Share The following table sets forth the computation of basic and diluted net loss per share of common stock for the years ended December 31, 2024 and 2023 (in thousands, except share and per share data):

|                                                                                            |     | Year ended December 31, |       2024 |   |     |   |      2023 |   |
|:-------------------------------------------------------------------------------------------|:----|:------------------------|-----------:|:--|:----|:--|----------:|:--|
| Net loss                                                                                   |     | $                       |    (63,102 | ) |     | $ |    (6,275 | ) |
| Weighted average common shares used in computing net loss per share, basic and diluted (1) |     |                         | 10,175,580 |   |     |   | 8,011,802 |   |
| Net loss per share, basic and diluted                                                      |     | $                       |      (